Latest 20-F annual reports

Santech Holdings Limited has completed a major corporate restructuring, exiting wealth and asset management to focus on early-stage technology ventures, reporting a significant net loss for fiscal year 2025.

CLPS Incorporation reported a net loss of $6.4 million in fiscal year 2025 despite a 15.2% revenue increase, driven by strong IT consulting demand and global expansion.

Dogness (International) Corporation announced a 39.5% revenue increase to $20.7 million and a 60.9% gross profit rise in fiscal year 2025, driven by intelligent pet products and climbing hooks.

Recon Technology, Ltd. reported a 3.7% revenue decrease and a 27.0% gross profit decline for fiscal year 2025, impacted by falling oil prices and operational setbacks, despite an improved net loss.

Critical Metals Corp. filed an amendment to its annual report to incorporate Tanbreez financial statements and clarify its clawback policy following a prior financial restatement.

Tungray Technologies Inc. filed an amended annual report revealing a shift to a net loss of $0.6 million in 2024 from a net income in 2023, alongside a 10.8% revenue decrease.

JBDI Holdings Limited reported a net operating loss of $2.9 million for the financial year ended May 31, 2025, a significant increase from the $1.0 million loss in the prior year, alongside a 10.1% revenue decrease.

IperionX Limited has transitioned to a commercial titanium producer in the U.S., scaling production capacity and securing significant government funding for its Virginia facility and Tennessee critical minerals project.

DEFSEC Technologies Inc. filed an amendment to its annual report clarifying its corporate governance practices, electing to follow Canadian home country rules over certain Nasdaq listing requirements.

Linkers Industries Limited reported a significant increase in net loss for fiscal year 2025, alongside a Nasdaq bid price non-compliance notice, despite completing its initial public offering.

China Natural Resources, Inc. filed an amendment to its annual report, addressing SEC comments and disclosing substantial doubt about its ability to continue as a going concern.

Critical Metals Corp. announced an amendment to its Tanbreez acquisition agreement, increasing its potential ownership to 92.5% while reporting a reduced net loss and improved equity position for fiscal year 2025, despite ongoing liquidity concerns and internal control deficiencies.

Critical Metals Corp. has filed an amended annual report, restating prior financial statements due to errors in warrant valuation and disclosing a new material weakness in internal controls, raising substantial doubt about its going concern ability.

Grupo Simec filed an amendment to its 2024 annual report to include separate CEO and CFO certifications on the effectiveness of disclosure controls and internal financial reporting controls.

Viomi Technology Co., Ltd. reported a net income of RMB63.4 million in 2024, a significant turnaround from previous losses, driven by a strategic divestiture and focus on home water solutions.

TMD Energy Limited reported a significant net loss of $4.52 million and a 22.7% revenue decline for the six months ended June 30, 2025, primarily due to global trade tensions and lower oil prices.

Immuron Limited's latest 20-F filing reveals significant revenue growth for its commercial products and progress in its clinical-stage drug candidates for infectious diseases.

New Oriental Education & Technology Group Inc. reported a 13.6% increase in total net revenues to US$4.9 billion for fiscal year 2025, driven by educational services growth, despite a decline in private label product sales and a goodwill impairment.

Eason Technology Limited reports a significant net loss in 2024, driven by the divestiture of its microfinance business and a strategic pivot to real estate and digital security.

Jiuzi Holdings Inc. filed an Amendment No. 3 to its annual report on Form 20-F to replace inadvertently erroneous CEO and CFO certifications.

EUDA Health Holdings Limited filed an amended annual report for 2024, revealing a significant net loss, accumulated deficit, and substantial doubt about its ability to continue as a going concern, despite a strategic shift to holistic wellness.

Cordyceps Sunshine Biotech Holdings Co., Ltd. filed an amended annual report for 2023, restating financial results and detailing a strategic spin-off of its Cordyceps business to focus on Cattle camphor mushroom products.

Elong Power Holding Limited reported a significant net loss of $30.1 million in 2024, alongside a sharp revenue decline and Nasdaq delisting warnings, raising substantial doubt about its going concern ability.

Nova Minerals Limited reports significant progress at its Estelle Gold and Critical Minerals Project in Alaska, with updated gold resources, new antimony discoveries, and a strategic dual-commodity development pathway.

Manchester United plc reported a significant reduction in its annual loss for fiscal year 2025, driven by commercial growth and lower employee costs, despite a notable decline in broadcasting revenue due to a weaker on-field performance.

Phaos Technology Holdings reported a significant increase in net loss and negative cash flow for fiscal year 2025, raising substantial doubt about its ability to continue as a going concern, despite an upcoming IPO.

Tantech Holdings Ltd. filed an amended annual report, disclosing a new $2.16 million promissory note, updated financial statements, and expanded risk factors related to its China-based operations.

Radiopharm Theranostics reported a reduced comprehensive loss in fiscal 2025, driven by increased revenue and R&D tax incentives, while advancing multiple radiopharmaceutical drug candidates through clinical trials.

Magnitude International Ltd. reported a significant decrease in revenue and net profit for the fiscal year ended April 30, 2025, despite completing its initial public offering.

Opthea Limited has ceased development of its lead drug candidate, sozinibercept, for wet AMD after Phase 3 trial failures, settling a major funding agreement and initiating a strategic review for new therapeutic applications.